• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

MGC Pharmaceuticals Shares Are Up after 85% increased PO (ASX:MXC)

Like 0

By Lachlann Tierney, Wednesday, 03 March 2021

The MGC Pharmaceuticals Ltd [ASX:MXC] share price is up after its leading European distributor increased purchase order volume of MGC’s ArtemiC by 85%. The MGC share price jumped 7% in early trading...

The MGC Pharmaceuticals Ltd [ASX:MXC] share price is up after its leading European distributor increased purchase order volume of MGC’s ArtemiC by 85%.

The distributor Swiss PharmaCan AG (SPC), upped its order following an initial agreement which was reached in February.

MGC’s ArtemisC products have an anti-inflammatory effect and according to the company, can ‘prevent deterioration of COVID-19 patients and achieve faster clinical improvement.’

The MGC share price jumped 7% in early trading, peaking as high as 8.6 cents but later settling largely flat with the share price up 1.25% at the time of writing.

Four Innovative Aussie Small-Cap Stocks That Could Shoot Up

Despite the early spike, MGC’s shares are still down from the 13-cent YTD peak.

ASX MXC Share Price Chart - MGC Pharmaceuticals Ltd SharesSource: ASX

Let’s take a deeper look at MGC’s announcement.

MCG share price up on increased purchase order volume

Here are the key highlights:

  • ‘In February 2021, MGC Pharma signed an exclusive Master Agreement with leading European nutraceuticals producer and distributor, Swiss PharmaCan AG (SPC), for the worldwide supply and distribution of ArtemiC Rescue as a food supplement for a 3-year minimum period
  • ‘This Master Agreement follows the completion of a successful Phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients across Israel and India that met all its primary and secondary endpoints (per ASX releases in 2020)
  • ‘SPC’s initial purchase order for ArtemiC Rescue has now been increased by 85% from the initial ArtemiC Rescue wholesale order received in February on signing, increasing this first order to in excess of $425,00 (+£275,000) wholesale revenue to MGC Pharma
  • ‘The Master Agreement includes a minimum wholesale order quantity to MGC Pharma of 40,000 units per quarter of ArtemiC Rescue
  • ‘Swiss PharmaCan AG to exclusively distribute ArtemiC Rescue worldwide, with specific focus on countries currently reporting high numbers of COVID-19
  • ‘The Company has sufficient manufacturing capacity at its production facility in Slovenia to produce commercial scale batches of ArtemiC rescue for distribution by Swiss PharmaCan AG.’

The main takeaway here is the big tick of approval for MGC’s food supplement product by a large nutraceutical’s distributor.

It is a sign of confidence for MGC that leading distributors are wishing to up their orders and enter into exclusive distribution agreements with it.

MGC’s co-founder and managing director, Roby Zomer, commented that ‘this further agreement will provide more people access to natural therapeutic benefits of the supplement and ease suffering following the successful phase II trial results in December.’

MCG’s streak of positive news continues

The announcement follows a streak of positive news for MGC.

As we’ve covered earlier here on Monday Morning, in February MCG became the first pot stock to list on the London Stock Exchange (LSE).

The company also reported successful Phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients late last year.

Outlook for MXC share price

What can today’s MXC share price tapering off suggest?

Although the order increase is good news, investors may not have been too impressed that this increase only led to $425,00 in wholesale revenue to MGC.

This is especially so considering MGC’s half yearly report released this February showed a consolidated loss of $5.9 million and revenue down a significant 58%.

Nevertheless, in that report the company stated that ‘following the London Stock Exchange listing and associated share placement, the Group is in a strong financial position to pursue identified growth initiatives.’

Their half yearly shows a cash balance of $1.5 million, and subsequent to the report a capital raise of around $11.7 million.

Not the worst cash position, given a variety of factors, including the increased appetite by investors for pot stocks.

The MGC share price outlook depends heavily on how well it can progress with its key clinical research programs and how well it can scale the distribution of its widening product range.

Investors may feel that today’s ASX announcement did not provide sufficient information to judge one way or the other.

Additionally, as our Money Morning analyst Lachlann Tierney said recently regarding the outlook for MXC shares, the fact that today’s early trading spike in the MXC share price fell flat ‘means a number of investors may have taken the opportunity to exit on a high note.’

If you’re interested in pot stocks like MXC and are looking for more pot stock ideas, do make sure to check out our new free report.

This report assesses the state of the industry and looks at three stocks that are brimming with potential for 2021.

Get your full copy, for free, right here.

Regards,

Lachlann Tierney
For Money Morning

 

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • China’s Game of Commodity Chicken
    By Charlie Ormond

    When commodities become weapons instead of just market goods, traditional investing rules break down.

  • Ride Mining’s Profitable ‘Curve’ this Way
    By Callum Newman

    All week we’ve been on a mission. We’re unpicking the dynamics around gold, and gold stocks. Here’s a bit of advice on this opportunity,

  • Silver & Platinum Squeeze Higher
    By James Cooper

    Cycle Turns: Silver and Platinum on the move… Is it their industrial or precious metal angle that’s getting investors interested?

Primary Sidebar

Latest Articles

  • China’s Game of Commodity Chicken
  • Ride Mining’s Profitable ‘Curve’ this Way
  • Silver & Platinum Squeeze Higher
  • One forecast for gold: 10k per ounce!
  • Three men, $20.8 million, and a $230 million rally… all in a day

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988